The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Aim of the study: B-Lymphocyte Stimulator (BLyS), a key regulator of B-cell homeostasis, was recently involved in the regulation of malignant cell survival in both hematological and non-hematological cancers. In this study we analyzed the possible role of BLyS in neuroendocrine tumors (NET). Methods: Sixty-two consecutive unselected patients with a diagnosis of NET were enrolled in the study. According to the clinical course, patients were classified in 3 subgroups: patients with evidence of persistent but stable disease (n = 19), patients in remission (n = 13) and patients with evidence of recurrent disease (progressive patients, n = 30). Patients were compared to 77 sex-matched blood donors (HBDs). BLyS and Chromogranin A (CgA) serum levels were analyzed by ELISA. Results: Overall, NET patients presented more elevated BLyS levels than HBDs (1195± 568 pg/ml vs 666± 240 pg/ml; p < 0.0001) and BLyS levels correlated with tumor differentiation. Patients with stable disease or in remission presented with significant lower BLyS levels than patients with disease progression (906±273 pg/ml versus 1503±637 pg/ml; p < 0.0001). Patients with metastases displayed higher BLyS levels than patients without metastases (1391±724 pg/ml versus 1079±422 pg/ml; p=0.022). Of note, BLyS levels during the follow-up (after 6.6±2.8 months) demonstrated a significant increase in progressive patients (from 1576±927 pg/ml to 2003±1268 pg/ml; p=0.0107), while remained substantially unchanged in stable/remission cases (from 1103±427 pg/ml to 1060±400 pg/ml; p=0.52). In contrast, CgA in the same series showed contradictory change Conclusions: Elevated BLyS levels characterized patients with NET and BLyS appears as a new potential marker in the management of these neoplastic diseases..
Media Type: |
Electronic Article |
---|
Year of Publication: |
2011 |
---|---|
Publication: |
2011 |
Contained In: |
To Main Record - volume:11 |
---|---|
Contained In: |
Immunology, endocrine & metabolic agents in medicinal chemistry - 11(2011), 4, Seite 306-314 |
Language: |
English |
---|
Contributors: |
Fabris, Martina [Author] |
---|
Links: |
---|
BKL: |
---|
Supporting institution / Project title: |
|
---|
PPN (Catalogue-ID): |
OLC1986720039 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC1986720039 | ||
003 | DE-627 | ||
005 | 20230518181148.0 | ||
007 | cr uuu---uuuuu | ||
008 | 170131s2011 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a fidpha_zeitschriften_20170130.pp |
035 | |a (DE-627)OLC1986720039 | ||
035 | |a (DE-599)GBVOLC1986720039 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |
084 | |a PHARM |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Fabris, Martina |e verfasserin |4 aut | |
245 | 1 | 0 | |a The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases |
264 | 1 | |c 2011 | |
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Aim of the study: B-Lymphocyte Stimulator (BLyS), a key regulator of B-cell homeostasis, was recently involved in the regulation of malignant cell survival in both hematological and non-hematological cancers. In this study we analyzed the possible role of BLyS in neuroendocrine tumors (NET). Methods: Sixty-two consecutive unselected patients with a diagnosis of NET were enrolled in the study. According to the clinical course, patients were classified in 3 subgroups: patients with evidence of persistent but stable disease (n = 19), patients in remission (n = 13) and patients with evidence of recurrent disease (progressive patients, n = 30). Patients were compared to 77 sex-matched blood donors (HBDs). BLyS and Chromogranin A (CgA) serum levels were analyzed by ELISA. Results: Overall, NET patients presented more elevated BLyS levels than HBDs (1195± 568 pg/ml vs 666± 240 pg/ml; p < 0.0001) and BLyS levels correlated with tumor differentiation. Patients with stable disease or in remission presented with significant lower BLyS levels than patients with disease progression (906±273 pg/ml versus 1503±637 pg/ml; p < 0.0001). Patients with metastases displayed higher BLyS levels than patients without metastases (1391±724 pg/ml versus 1079±422 pg/ml; p=0.022). Of note, BLyS levels during the follow-up (after 6.6±2.8 months) demonstrated a significant increase in progressive patients (from 1576±927 pg/ml to 2003±1268 pg/ml; p=0.0107), while remained substantially unchanged in stable/remission cases (from 1103±427 pg/ml to 1060±400 pg/ml; p=0.52). In contrast, CgA in the same series showed contradictory change Conclusions: Elevated BLyS levels characterized patients with NET and BLyS appears as a new potential marker in the management of these neoplastic diseases. | ||
700 | 1 | |a Tonutti, Elio |e verfasserin |4 aut | |
700 | 1 | |a Panighel, Carolina |e verfasserin |4 aut | |
700 | 1 | |a Blasone, Nadia |e verfasserin |4 aut | |
700 | 1 | |a Visentini, Daniela |e verfasserin |4 aut | |
700 | 1 | |a Pizzolitto, Stefano |e verfasserin |4 aut | |
700 | 1 | |a De Maglio, Giovanna |e verfasserin |4 aut | |
700 | 1 | |a Isola, Miriam |e verfasserin |4 aut | |
700 | 1 | |a Curcio, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Grimaldi, Franco |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Immunology, endocrine & metabolic agents in medicinal chemistry |d San Francisco, Calif. : Bentham Science Publ., 2006 |g 11(2011), 4, Seite 306-314 |w (DE-627)507526643 |w (DE-600)2221719-8 |w (DE-576)435514261 |x 1871-5222 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2011 |g number:4 |g pages:306-314 |
856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5222&volume=11&issue=4&spage=306 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_20 | ||
936 | b | k | |a 44.40 |q AVZ |
951 | |a AR | ||
952 | |d 11 |j 2011 |e 4 |h 306-314 |